Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GH Research ( (GHRS) ) just unveiled an announcement.
On June 20, 2025, GH Research PLC announced that it submitted a complete response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001. The submission, made ahead of schedule, addresses the FDA’s requests with comprehensive data and completed toxicology studies, potentially impacting the treatment of treatment-resistant depression.
The most recent analyst rating on (GHRS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing transformative treatments for depression. Their lead product candidate, GH001, is designed for mebufotenin administration via a proprietary inhalation method, showing promising results in clinical trials.
Average Trading Volume: 182,797
Technical Sentiment Signal: Strong Buy
Current Market Cap: $734.4M
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.